Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis
Jordan Gauthier(Seattle Cancer Care Alliance), Tony Chour(University of Washington), Erik L. Kimble(University of Washington), David G. Maloney(Fred Hutch Cancer Center), Aiko Torkelson(Fred Hutch Cancer Center), Qian Wu(Cancer Research Center), Andrew J. Portuguese(University of Washington), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Mazyar Shadman(University of Washington), Delaney Kirchmeier(Fred Hutch Cancer Center), Filippo Milano(Fred Hutch Cancer Center), Lorenzo Iovino(University of Pisa), Evan W. Newell(Agency for Science, Technology and Research), Folashade Otegbeye(University Hospitals of Cleveland), Aya Albittar(University of Washington), Ryan D. Cassaday(University of Washington), Abigail Chutnik(Fred Hutch Cancer Center), Nikki Pin(Fred Hutch Cancer Center), Joseph De Los Reyes(Fred Hutch Cancer Center), Jennifer J. Huang(Stanford Medicine), Sylvain Simon(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Barbara Pender(Fred Hutch Cancer Center)
Cited by 2